Atezolizumab generic Atezolizumab is a programmed death ligand 1 (PD-L1) monoclonal antibody. It acts by activating the anti-tumor immune response and is prescribed for the treatment of advanced or metastatic urothelial carcinoma (a type of cancer which affects the urinary bladder and its related parts). Metastatic cancer refers to a cancer that has spread to distant parts of the body. Atezolizumab is approved for use in patients who have disease progression. • During or following chemotherapy which contains a platinum-based drug in the regimen. • With platinum-based chemotherapy administered either before or after surgery for the cancer.
More Info about Atezolizumab